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Summary. Background: Previous studies have suggested that
levels of inﬂammatory mediators are risk indicators for venous
thrombotic disease. We have sought to conﬁrm and extend
these ﬁndings by measuring plasma tumor necrosis factor
(TNF)-a, interleukin (IL)-1b, IL-6, IL-8, IL-10 and IL-12p70
levels in a case–control study for venous thrombotic disease.
Methods: The plasma levels of these inﬂammatory mediators
were measured by ﬂow cytometric analysis using a multiplexed
bead assay. Patient and control samples came from the Leiden
Thrombophilia Study (474 controls and 474 patients).
Results: In a subset of patients and controls inﬂammatory
mediators aredetectable inplasma.The crudeodds ratios (ORs)
associated with the presence of detectable markers were 2.1
[TNF-a, 95% conﬁdence interval (CI) 1.1, 3.9], 1.7 (IL-1b, 95%
CI 1.1, 2.9), 2.4 (IL-6, 95% CI 1.9, 5.3), 2.8 (IL-8, 95% CI 1.8,
4.4), 0.8 (IL-10, 95% CI 0.3, 1.8), and 1.3 (IL-12p70, 95% CI
0.9, 2.0). Adjustment for putative confounders did not inﬂuence
the risk estimates. Conclusion: TNF-a, IL-6, and IL-8 levels
are risk determinants for venous thrombosis. Individuals with
detectable levels of either of these mediators in plasma have an
OR of about 2. In line with these ﬁndings, the odds for the anti-
inﬂammatory cytokine Il-10 tend to be <1. These results add
further evidence for the contention that there is an inﬂamma-
tory component to venous thrombotic disease andmay explain
why anti-inﬂammatory agents such as aspirin may be effective
for prevention.
Keywords: chemokine, cytokine, inﬂammation, risk factor,
venous thrombosis.
Introduction
Venous thrombosis is a common disorder with an annual
incidence of 1–3 per 1000 [1,2]. It manifests itself mainly as
deep-vein thrombosis of the leg and pulmonary embolism.
Classical risk factors are immobilization (plaster casts, surgery,
air travel) and cancer [3]. In recent decades, much progress has
been made in the identiﬁcation of hypercoagulability as a risk
factor for thrombosis. These include abnormalities in the
coagulation system (deﬁciencies of protein C, protein S,
antithrombin, factor V Leiden, prothrombin 20210A, high
levels of clotting factor (F)VIII, factor IX, factor XI) as well as
the use of female hormones (oral contraceptives, postmeno-
pausal replacement therapy) [4,5].
Recently, several studies have suggested a role for inﬂam-
matory markers in the etiology of venous thrombosis, follow-
ing similar reports in arterial disease [6,7]. Even though venous
thrombosis is not characterized by a chronic systemic inﬂam-
matory disease such as atherosclerosis in arterial disease, we
hypothesized that an inﬂammatory response, regardless of its
origin, could lead to hypercoagulability and hence increase the
risk of venous thrombosis. Previously we have shown increased
levels of interleukin (IL)-8 in patients with recurrent thrombosis
and in patients with a ﬁrst event of venous thrombosis
compared with healthy controls [7]. We also found elevated
levels of C-reactive protein (CRP) in patients who had suffered
thrombosis [8]. We have sought to conﬁrm and extend these
ﬁndings by measuring plasma tumor necrosis factor (TNF)-a,
IL-1b, IL-6, IL-8, IL-10, and heterodimeric IL-12 (IL-12p70)
levels in a case–control study for venous thrombotic disease.
Methods
Patients and controls
Patients were participants in the Leiden Thrombophilia Study,
and were consecutive patients diagnosed by objective methods
with a ﬁrst deep vein thrombosis between 1988 and 1992,
recruited from three Anticoagulation Clinics [9]. Inclusion
criteria were age 18–70 years and the absence of overt
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malignancy. Controls were recruited via the patients and were
either friends of patients or partners of (other) patients.
Controls were matched for age (±5 years) and sex.
All patients and controls were interviewed in person with
regard to putative risk factors for thrombosis, comorbid
conditions and use of medicinal drugs. Patients were seen at
least 6 months after the discontinuation of oral anticoagulant
treatment for blood collection (unless this treatment was
prescribed indeﬁnitely and could not be interrupted). Blood
was taken in Sarstedt Monovettes, as 106 mM citrated plasma
and stored at )70 C.
Cytokine assays
A commercially available multiplex cytometric bead assay was
employed for the simultaneous measurement of IL-1b, IL-6,
IL-8, IL-10, IL-12p70, and TNF-a (BD Biosciences, Alphen
aan den Rijn, the Netherlands). In brief, 10 lL of thawed
plasma were mixed with 10 lL 1 : 10 diluted capture bead
suspension in a sample tube. Subsequently 10 lL of PE-labeled
detection reagent were added to the assay tubes followed by
incubation in the dark for 3 h. Wash buffer was added
(200 lL) and the tubes were centrifuged at 200 · g followed by
careful aspiration of the supernatant and gentle resuspension of
the bead pellet in 150 lL of wash buffer. All reagents and
buffers were supplied by the manufacturer. The ﬁnished bead
suspensions were analyzed on a FACSCalibur ﬂow cytometer
(Becton Dickinson Biosciences, Alphen aan den Rijn, the
Netherlands) according to the instructions of the bead assay
manufacturer. The detection limit of each of the cytokines was
2.5 pg mL)1. In total 932 samples were analyzed.
Statistical analysis
We calculated odds ratios (ORs) asmeasures of relative risk, by
cross tabulation and logistic regression. Conﬁdence intervals
(95% CI) were calculated according to Woolf or derived from
the model [10]. Various cut-off points for cytokine levels were
used to delineate normal from elevated, i.e. in a ﬁrst analysis
as not detectable vs. detectable, and in a second analysis
for more pronounced elevated levels, i.e. >50 pg mL)1
for IL-12p70, >20 pg mL)1 for IL-1b and IL-8, and
>10 pg mL)1 for TNF-a, IL-10 and IL-6. The latter was
roughly equivalent to levels in the highest 5% of the
distribution in healthy individuals. We performed analyses
adjusted for age and sex by logistic modeling. In addition, we
examined correlation between levels of various markers with
correlation analysis. The effect of time since event on marker
levels was assessed by linear regression.
Results
We included 474 patients and 474 controls, for whom plasma
was available for 470 in each group. In the majority of patients
and controls, no inﬂammatory markers could be detected,
while detectable levels were present in varying numbers of
patients and controls (2–16% for the various markers). When
inﬂammatory markers were detectable, they had a wide range
of values (Table 1).
Detectable levels were found more often in patients than in
controls for all markers except IL-10. Table 2 shows the ORs
associated with the presence of detectable markers, which were
elevated for all markers except IL-10 (and only marginally so
Table 1 Detectable levels of inﬂammatory markers in cases and controls
Analyte
Cases (n ¼ 470) Controls (n ¼ 470)
Detectable
n (%)
Range
(pg mL)1)
Median
(pg mL)1)
Detectable
n (%)
Range
(pg mL)1)
Median
(pg mL)1)
TNF-a 30 (6.3) 0–212 15.9 15 (3.2) 0–95.6 12.4
IL-1b 40 (8.5) 0–387 12.3 24 (5.1) 0–162 16.4
IL-6 21 (4.4) 0–232 20.5 9 (1.9) 0–192 29.4
IL-8 73 (15.5) 0–213 10.4 29 (6.2) 0–112 7.6
IL-10 10 (2.1) 0–54 10.5 13 (2.8) 0–186 15.3
IL-12p70 56 (11.9) 0–945 20.8 44 (9.4) 0–1384 21.6
For abbreviations see text.
Table 2 Odds ratios (OR) for the presence of detectable inﬂammatory markers
Adjustment factors
TNF-a
OR
(95% CI)
IL-1b
OR
(95% CI)
IL-6
OR
(95% CI)
IL-8
OR
(95% CI)
IL-10
OR
(95% CI)
IL-12p70
OR
(95% CI)
None 2.1 1.7 2.4 2.8 0.8 1.3
(1.1–3.9) (1.1–2.9) (1.9–5.3) (1.8–4.4) (0.3–1.8) (0.9–2.0)
Age, sex 2.1 1.7 2.4 2.8 0.8 1.3
Age, sex, CRP 2.0 1.7 2.0 2.7 0.7 1.3
Age, sex, CRP, FVIII 1.8 1.6 1.9 2.5 0.6 1.1
CRP, C-reactive protein; FVIII, coagulation factor VIII. For other abbreviations see text.
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for IL-12). We subsequently sought to explain the association
by adjustment for putative confounders (viz. sex, age, CRP,
coagulation FVIII), which, however, did not affect the risk
estimates. In patients, time between the event and blood
collection ranged from 6 months to nearly 6 years. In linear
regression analysis, there was no association between the time
since the event and the level of inﬂammatory markers
(regression coefﬁcient ranging from )0.104 (IL-10) to 2.5
(IL-12), i.e. a decrease or an increase per year of
<2.5 pg mL)1, with all conﬁdence intervals around the null
value).
A second analysis aimed at high levels of IL12p70
(>50 pg mL)1, n ¼ 26), IL-1b (>20 pg mL)1, n ¼ 25), IL-8
levels (>20 pg mL)1, n ¼ 23), TNF-a (>10 pg mL)1,
n ¼ 29), IL-10 (>10 pg mL)1, n ¼ 16) and IL-6
(>10 pg mL)1, n ¼ 22), compared with those with lower or
non-detectable levels, led to similar or more pronounced
results. For IL-12p70 there was no association with venous
thrombosis (OR ¼ 1.0, 95% CI 0.5, 2.2), and for TNF-a
(OR ¼ 2.3, 95%CI 1.1, 5.1), IL-6 (OR¼ 2.2, 95%CI 0.9, 5.4),
IL-1b (OR¼ 1.5, 95%CI 0.7, 3.4) risk estimates were similar to
the previous analysis. For high IL-10 levels the association with
(the absence of) thrombosis became stronger (OR ¼ 0.4, 95%
CI 0.2, 1.3), as was the case for high levels of IL-8 (OR ¼ 4.9,
95% CI 1.7, 15.4).
In summary, TNF-a, IL-6, and IL-8 levels are risk determi-
nants for venous thrombosis. Overall, individuals that have
detectable levels of either of these mediators in their plasma
have a 2-fold increased risk. For IL-8 in particular, this risk
seemed to increase with the actual level observed. In line with
these ﬁndings, the risk for the anti-inﬂammatory cytokine IL-
10 tended to be decreased. No association was apparent for
levels of IL-12, while the association was weak for IL-1b levels.
Conclusion
The cytokine and chemokine family consists of a multitude of
proteins with differing and partly overlapping functions in
innate and acquired immunity. We measured the levels of six
distinct cytokines and chemokines. We were guided in our
choice by the availability of a commercial kit that enabled the
simultaneous and rapid measurement of all six proteins in a
very small volume of plasma (10 lL). TNF-a, IL-6, IL-8, and
IL-10 are key players in innate host defense.With the exception
of IL-8, these proteins are generally not detectable in plasma of
healthy individuals. In human models of controlled inﬂamma-
tion using endotoxemia administration, rapid rises are
observed in the blood [11]. In suchmodels the proinﬂammatory
mediator TNF-a appears ﬁrst, followed by increases in
proinﬂammatory IL-6, IL-8, and the anti-inﬂammatory medi-
ator IL-10 [11]. IL-1b responds with a minor increase in
endotoxemia models, whereas levels of IL-12p70 do not
respond to such an inﬂammatory challenge [12,13].
Remarkably, differences in plasma levels between patients
and controls seem to agree well with plasma alterations in
endotoxin models. In particular, the fact that the OR for
IL-12p70 is close to 1 agrees with the fact that this cytokine
does not repond to endotoxin in vivo. These data therefore
indicate that the inﬂammatory state of venous thrombotic
individuals represents an activation of the innate immune
response.
In this study, blood collection took place after the throm-
botic event. Therefore, an inﬂammatory reaction as a conse-
quence rather than a cause of venous thrombosis cannot be
ruled out. The absence of any attenuation of elevated levels
with a larger time between the thrombotic event and the date of
the blood draw argues against a post-thrombotic effect, unless
this would be persistent over protracted periods of time.
Prospective studies will be required to elucidate this issue
further. If inﬂammation is indeed a cause of venous thrombo-
sis, this may explain the weak antithrombotic effect of aspirin
[14], and identiﬁcation of individuals with high levels of
inﬂammatory markers could assist in targeting this therapy,
which has a lower risk of hemorrhagic complications that
standard anticoagulant treatment.
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